Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial is to determine the safety of an intravenously
administered radioisotope, RAD301 ([68Ga]-Trivehexin), in either health volunteers or
patients with pancreatic cancer.
All subjects will undergo:
Screening, which entails physical examination and blood samples for standard blood testing.
Subjects that successfully pass screening will undergo:
Gallium-68 PET scanning procedures, which will occur during a single day (about 5-6 hours).
These subjects will return to the clinic at 2 weeks for additional safety labs. All scanned
subjects will also be evaluated by telephone follow up on a weekly basis for 1 month after
scanning.